Navigation Links
Organovo Announces Relocation and Commencement of Operations at Larger Facility
Date:7/17/2012

SAN DIEGO, July 17, 2012 /PRNewswire/ -- Organovo Holdings, Inc. (OTCQB: ONVO), a biotechnology company focused on delivering breakthrough three-dimensional (3D) bioprinting technology, today announced a facility relocation and expansion.  Organovo has moved its headquarters to a new 15,539 sq ft facility in San Diego, California. The facility consists of mixed lab and office space and features a clean room space nearly four times larger than Organovo's previous facility.  Clean room facilities are required for protection of the functional human tissues created by Organovo's innovative 3D bioprinting process.

The space is located in the Portola development in the Sorrento Mesa area of San Diego. Alexandria Real Estate is the property owner and manager through its regional LLC.  Cushman and Wakefield, LLC brokered the transaction, with Brent Jacobs and Greg Bisconti of the life sciences group representing Organovo. Organovo's previous headquarters facility consisted of 4,432 sq ft of mixed office and lab space. In the expanded facility, Organovo will continue its focus on developing bioprinting to create a broad array of functional 3D tissues that can recapitulate in vivo biology for human disease research, drug discovery and development, toxicology testing and, eventually, as therapies.

"Organovo's facility expansion provides a state-of-the-art space for our team to drive innovation with our research and development initiatives and supports partnering activities with our bioprinting technologies," commented Keith Murphy, chairman and chief executive officer of Organovo.  "We now have the space to expand our expertise into additional areas of research and development and to expand our bioprinting capacity with up to four NovoGen MMX Bioprinters in regular operation. The new facility provides essential resources for Organovo to advance the development of new bioprinter technologies, 3D drug discovery models, and 3D cellular assays and research to create functional human tissues for surgical transplant."

About Organovo Holdings, Inc.

Organovo is a three-dimensional biology company focused on delivering breakthrough bioprinting technology and creating tissue on demand for research and medical applications. The company's NovoGen three-dimensional bioprinting technology is a platform that works across all tissue and cell types. Organovo's NovoGen MMX Bioprinter was selected as one of the "Best Inventions of 2010" by TIME Magazine. Organovo is helping pharmaceutical partners develop human biological disease models in three dimensions that enable therapeutic drug discovery and development. Organovo's bioprinting technology can also be developed to create surgical tissues as direct therapy. Organovo leads the way in solving complex medical research problems and building the future of medicine. For more information, please visit http://www.organovo.com.  

Safe Harbor Statement

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including, our most recent Quarterly Report on Form 10-Q. We do not undertake to update these forward-looking statements made by us.

 


'/>"/>
SOURCE Organovo Holdings, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Organovo Announces Close of $15.2 Million Private Placement to Advance 3D Bioprinting for Medical Applications
2. Organovo, Inc. Investor Presentation Now Available for On-Demand Viewing at RetailInvestorConferences.com
3. Organovo, Inc. to Webcast, Live, at RetailInvestorConferences.com on March 1st
4. Organovo to Present at Lazard Capital Markets 8th Annual Healthcare Conference
5. BioStorage Technologies Continues Global Growth; Announces Strategic Expansion Into Asia Pacific and New General Manager APAC
6. Silence Therapeutics Announces Subscription and Open Offer to Raise up to £5.7 Million
7. GenoSpace Announces the Launch of a Cloud-Based "Information Ecosystem" for Advancing 21st-Century Personalized Medicine
8. Inclinix-PMG Holdings, Inc. Announces Executive Management Changes
9. MetaStat, Inc. Announces Allowance of Patent Claims
10. Nektar Therapeutics Announces Private Placement of $125 Million of Senior Secured Notes Due in 2017
11. PROLOR Biotech Announces Presentation of Data on Its Long-Acting Clotting Factors at World Federation of Hemophilia World Congress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 2016  Alex,s Lemonade Stand Foundation (ALSF), a leading ... open a state-of-the-art bioinformatics lab, using ,big data, to ... comes as Liz Scott , co-executive director of ... Summit in Washington, D.C. , hosted ... and advocate of pediatric cancer research and awareness. ...
(Date:6/27/2016)... June 27, 2016  Global demand for enzymes ... through 2020 to $7.2 billion.  This market includes ... cleaning products, biofuel production, animal feed, and other ... and biocatalysts). Food and beverages will remain the ... increasing consumption of products containing enzymes in developing ...
(Date:6/27/2016)... GUELPH, ON , June 27, 2016 /PRNewswire/ - BIOREM ... it has been advised by its major shareholders, Clean ... LP, United States based venture ... common shares of Biorem (on a fully diluted, as ... for the disposition of their entire equity holdings in ...
(Date:6/27/2016)... SAN DIEGO , June 27, 2016  Sequenom, ... company committed to enabling healthier lives through the development ... Supreme Court of the United States ... Federal courts that the claims of Sequenom,s U.S. Patent ... the patent eligibility criteria established by the Supreme Court,s ...
Breaking Biology Technology:
(Date:6/27/2016)... 27, 2016 Research and Markets has announced ... report to their offering. ... to grow at a CAGR of 12.28% during the ... on an in-depth market analysis with inputs from industry experts. The ... coming years. The report also includes a discussion of the key ...
(Date:6/22/2016)... , June 22, 2016  The American College of ... Trade Show Executive Magazine as one of the fastest-growing ... May 25-27 at the Bellagio in Las Vegas ... the highest percentage of growth in each of the following ... exhibiting companies and number of attendees. The 2015 ACMG Annual ...
(Date:6/22/2016)... 2016   Acuant , the leading ... has partnered with RightCrowd ® to ... Management, Self-Service Kiosks and Continuous Workforce Assurance. ... functional enhancements to existing physical access control ... with an automated ID verification and authentication ...
Breaking Biology News(10 mins):